CDSCO Clarifies Approval Process for New Drugs With Global Trials

The Central Drugs Standard Control Organization (CDSCO) issued a critical clarification on August 10, 2026, regarding the regulatory pathway for new drug applications. The directive specifically addresses drugs that have not yet received approval in any other country but have undergone or are currently undergoing Phase III Global Clinical Trials (GCTs) involving Indian participants. These applications must now be processed by the Investigational New Drug (IND) Division at the CDSCO Headquarters in New Delhi.

The new mandate requires a rigorous and comprehensive evaluation of both clinical and non-clinical data. This process is governed by the provisions of the New Drugs and Clinical Trials Rules, 2019. By centralizing these applications, the CDSCO aims to ensure a standardized and thorough review process for innovative therapies that are being tested globally with Indian involvement, thereby enhancing the safety and efficacy standards for new medical interventions entering the domestic market.

This move is expected to streamline the approval timeline for pharmaceutical companies conducting multi-centric global trials. By providing a clear regulatory roadmap, the CDSCO is facilitating a more predictable environment for drug developers. Pharmaceutical firms must now ensure their data submission protocols align with the requirements of the IND Division to avoid delays in the approval process. This regulatory framework is essential for maintaining high standards in the introduction of novel drugs to the Indian healthcare system.